Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange (DFPP)

Grenoble Alpes University Hospital Center (CHU) logo

Grenoble Alpes University Hospital Center (CHU)




Kidney Transplantation
Antibody Mediated Rejection


Other: Sessions of news apheresis with double filtration
Other: Sessions of conventional apheresis

Study type


Funder types




Details and patient eligibility


In France around 90,000 cases of end-stage chronic kidney disease patients treated either by dialysis (60%) or renal transplantation (just over 40%). In terms of patient survival and quality of life and also economic reasons, the goal in France is to increase renal transplantation instead of patients on dialysis. After renal transplant, two main causes of the graft loss after the first years are death of patient with functioning graft, and chronic AntiBody Mediated Rejection (ABMR). Double Filtration PlasmaPheresis (DFPP) has never been evaluated for this indication. DFPP makes it possible to treat larger volumes of plasma than plasma exchange, and essentially eliminates higher molecular weights molecules including immunoglobulins comprising DSA (donor-specific alloantibody) but also the C1q involved in the lesions of(ABMR). It is postulated that it will be more effective in treating ABMR than usual plasma exchanges. A chronic ABMR is the result of the appearance de novo production of anti-Human Leucocyte Antigen antibodies (HLA) against one or more graft antigens (DSA: donor-specific alloantibody).These DSAs will lead to accelerated arteriosclerosis in the graft vessels, which will result in rapidly progressive renal failure, usually associated with a high rate of proteinuria. Numerous studies have shown that up to 20% of renal transplant patients develop DSA within 5 years of renal transplantation. Today, no treatment has been shown to be effective in the case of chronic ABMR: the basis of treatment is the reduction/elimination of DSA ( by apheresis for example) and the prevention of its re-synthesis B lymphocytes/plasma cells of the patient (with rituximab for example). The investigators of this study propose in the context of the active ABMR demonstrated by renal biopsy to evaluate in combination with rituximab, a new apheresis technique double Plasma filtration (DFPP) instead of plasma Exchange.

Full description

Each year in the Renal Nephrology and Transplantation Department of Grenoble Hospital treat about twenty renal transplant patients with chronic active antibody rejection. Some patients are diagnosed at a very advanced stage and will not be treated because the expected benefit is tenuous (exclusion criteria). For both groups, patients will have one session per day, 4 consecutive days then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment in all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2. At the beginning and at the end of each session, patients will have a blood test to measure the parameters and collection of study biological samples. DFPP sessions are performed by double filtration technique. A DFPP session lasts about 2 hours for 3.5 L of processed plasma. During the session it is necessary to compensate for 20 grams of albumin. The plasmapheresis sessions are performed by centrifugation technique. It takes about 20 minutes to prepare the apheresis monitor and circuit. A plasmapheresis session lasts approximately 1h30 for 3.5 L of plasma exchange (replacement with albumin), 2 h for an exchange where the removed plasma is replaced by fresh frozen plasma. The blood flow rate for plasmapheresis is 80 ml / min, or 50 ml / min a plasma flow rate. The study includes five follow-up visits following the treatment sessions. A visit 45 days after the start of apheresis sessions, a visit at 3 months and a visit every 3 months for one year.


16 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

To be enrolled into the study, subjects must meet all of the following inclusion criteria

  • Kidney transplantation for more than 6 months
  • The presence of one or more DSAs with MFI greater than 1000
  • Renal Graft dysfunction with renal biopsy of humoral rejection or chronic active antibody mediated rejection lesions based on the 2017 banff score ( with/without C4d)
  • Written informed consent in patients

Exclusion criteria

Subjects must not be enrolled into the study if they meet any of the following exclusion criteria:

  • Kidney transplant for less than 6 months.
  • MFI<1000
  • Hemoglobin level<110 g/l
  • No vascular access patients
  • Pre terminal histological lesions of chronic ABMR
  • Subject in exclusion period of another study
  • Pregnant women, parturient or breastfeeding
  • Subject under administrative or judicial control

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

16 participants in 2 patient groups

Plasma Exchange Group
Active Comparator group
Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
Other: Sessions of conventional apheresis
Double filtration PlasmaPheresis Group
Experimental group
Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
Other: Sessions of news apheresis with double filtration

Trial contacts and locations



Central trial contact

Farida Imerzoukene, ARC; Amjad UNEISI, ARC prom

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems